Global Melanoma Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The global melanoma cancer diagnostics market is projected to register a substantial CAGR of 7.2% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Global Melanoma Cancer Diagnostics Market, By Product Type (Instruments, Consumables and Accessories, and Others), Test Type (Biomarkers Test, Imaging Test, Biopsy, Fluorescent In Situ Hybridization (FISH) Tests, Comparative Genomic Hybridization (CGH) tests, Immunohistochemical (IHC) tests, and Others), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others), Distribution channel (Direct Tender and Retail Sales), Country (U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Denmark, Switzerland, Turkey, Sweden, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, UAE, Rest of the Middle East and Africa) Industry Trends and Forecast 2030

Some of the major factors contributing to the growth of the global melanoma cancer diagnostics market are:

Increase in prevalence of melanoma cancer

Rise in adoption of new technologies and easy accessibility for laboratory professionals

Market Players:

Some of the major players operating in the global melanoma cancer diagnostics market are:

Nanostring

Thermo Fisher Scientific Inc.

Quest Diagnostics Incorporated

Agilent Technologies, Inc

Qiagen, Inivata Ltd

F. Hoffman-La Roche Ltd

Abbott

AMLo Biosciences Limited

Myriad Genetics Inc.

Castle Biosciences

DermTech

Michael Diagnostics Ltd

Damae Medical

Skin Analytics

DermLite

DermaSensor

Skyline Dx

Neracare GmbH

VERISKIN INC.

Illumina Inc

bioMerieux SA

1 INTRODUCTION 49

1.1 OBJECTIVES OF THE STUDY 49
1.2 MARKET DEFINITION 49
1.3 OVERVIEW OF THE GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET 49
1.4 LIMITATIONS 51
1.5 MARKETS COVERED 51

2 MARKET SEGMENTATION 54

2.1 MARKETS COVERED 54
2.2 GEOGRAPHICAL SCOPE 55
2.3 YEARS CONSIDERED FOR THE STUDY 56
2.4 CURRENCY AND PRICING 56
2.5 DBMR TRIPOD DATA VALIDATION MODEL 57
2.6 MULTIVARIATE MODELLING 61
2.7 PRODUCT TYPE LIFELINE CURVE 61
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 62
2.9 DBMR MARKET POSITION GRID 63
2.10 MARKET END USER COVERAGE GRID 64
2.11 VENDOR SHARE ANALYSIS 65
2.12 SECONDARY SOURCES 66
2.13 ASSUMPTIONS 66

3 EXECUTIVE SUMMARY 67

4 PREMIUM INSIGHTS 69

4.1 PESTEL'S MODEL 72
4.2 PORTER'S FIVE FORCES MODEL 73

5 EPIDEMIOLOGY 74

6 INDUSTRY INSIGHTS 75

6.1 DEMOGRAPHIC TRENDS 75
6.2 KEY PRICING STRATEGIES 76
- 6.2.1 PRODUCT INNOVATION 76
- 6.2.2 CONSUMER AWARNESS 76
- 6.2.3 A VAST NETWORK OF DISTRIBUTION 76
- 6.2.4 PARTNERSHIP WITH POPULAR BRANDS BY MAJOR PLAYERS 77
- 6.2.5 OTHERS 77
6.3 KEY PATIENT ENROLLMENT STRATEGIES 77
- 6.3.1 IDENTIFICATION OF CUSTOMERS NEED FOR INNOVATIVE DIAGOSTIC PRODUCTS 77
- 6.3.2 INCREASING SPECIFIC TACTICS FOR EVERY STEP 77
- 6.3.3 EDUCATE AND COMMUNICATE 78
- 6.3.4 IMPROVING DIAGNOSIS SEEKING RATE 78
6.4 INTERVIEWS WITH MANUFACTURING COMPANIES 78

7 MARKET OVERVIEW 80

7.1 DRIVERS 82
- 7.1.1 GROWING PREVALENCE OF MELANOMA CANCER 82
- 7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 83
- 7.1.3 NOVEL TECHNOLOGIES IN MELANOMA CANCER DIAGNOSTICS 84
- 7.1.4 INCREASING AWARENESS REGARDING MELANOMA CANCER 85
7.2 RESTRAINTS 85
- 7.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 85
- 7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR MELANOMA CANCERS 86
7.3 OPPORTUNITIES 86
- 7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR MELANOMA CANCER TREATMENT 86
- 7.3.2 GOVERNMENT INITIATIVES TOWARD MELANOMA CANCER DIAGNOSTICS 87
- 7.3.3 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 88
- 7.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 88
7.4 CHALLENGES 89
- 7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF MELANOMA CANCER DIAGNOSTIC PRODUCTS 89
- 7.4.2 RADIATION RISKS FROM IMAGING TESTS 89

8 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 90

8.1 OVERVIEW 91
8.2 INSTRUMENTS 94
- 8.2.1 IMAGING INSTRUMENTS 95
  - 8.2.1.1 ULTRASOUND SYSTEMS 95
  - 8.2.1.2 MRI SYSTEMS 95
  - 8.2.1.3 CT SYSTEMS 95
  - 8.2.1.4 OTHERS 96
- 8.2.2 BIOPSY INSTRUMENTS 96
- 8.2.3 PATHOLOGY-BASED INSTRUMENTS 96
  - 8.2.3.1 PCR INSTRUMENTS 96
  - 8.2.3.2 CELL PROCESSORS 96
  - 8.2.3.3 SLIDE STAINING SYSTEMS 96
  - 8.2.3.4 TISSUE PROCESSING SYSTEMS 97
  - 8.2.3.5 OTHER PATHOLOGY-BASED INSTRUMENTS 97
8.3 CONSUMABLES & ACCESSORIES 97
- 8.3.1 KITS 98
  - 8.3.1.1 PCR KITS 98
  - 8.3.1.2 NUCLEIC ACID ISOLATION KITS 98
  - 8.3.1.3 DNA POLYMERASE KITS 98
  - 8.3.1.4 OTHERS 99
- 8.3.2 PROBES 99
  - 8.3.2.1 Q FISH 99
  - 8.3.2.2 FLOW FISH 99
  - 8.3.2.3 OTHERS 99
- 8.3.3 REAGENTS 99
  - 8.3.3.1 ASSAYS 100
  - 8.3.3.2 BUFFERS 100
  - 8.3.3.3 PRIMERS 100
  - 8.3.3.4 OTHERS 100
- 8.3.4 OTHER CONSUMABLES 100
8.4 OTHERS 100

9 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE 102

9.1 OVERVIEW 103
9.2 IMAGING TEST 106
- 9.2.1 ULTRASOUND 107
- 9.2.2 MRI 107
- 9.2.3 CHEST X-RAY 107
- 9.2.4 LYMPHOSCINTIGRAPHY 108
- 9.2.5 COMPUTED TOMOGRAPHY (CT) SCAN 108
- 9.2.6 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 108
- 9.2.7 OTHERS 108
9.3 BIOPSY 108
- 9.3.1 OPTICAL BIOPSY 109
- 9.3.2 EXCISIONAL BIOPSY 109
- 9.3.3 INCISIONAL BIOPSY 109
- 9.3.4 SHAVE BIOPSY 110
- 9.3.5 PUNCH BIOPSY 110
- 9.3.6 OTHERS 110
9.4 IMMUNOHISTOCHEMICAL (IHC) TESTS 110
- 9.4.1 S100 PROTEIN FAMILY BIOPSY 111
- 9.4.2 MELAN-A 111
- 9.4.3 PMEL/PMEL17/SILV/GP100 111
- 9.4.4 TYROSINASE 111
- 9.4.5 MITF 111
- 9.4.6 SM5-1 111
- 9.4.7 CSPG4/HMW-MAA 111
9.5 BIOMARKER TEST 112
- 9.5.1 BRAF MUTATION TEST 113
- 9.5.2 NRAS MUTATION TEST 113
- 9.5.3 CKIT TEST 113
- 9.5.4 OTHERS 113
9.6 FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS 113
9.7 COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS 114
9.8 OTHERS 115

10 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER 116

10.1 OVERVIEW 117
10.2 HOSPITALS 120
10.3 ASSOCIATED LABS 121
10.4 DIAGNOSTIC IMAGING CENTERS 121
10.5 INDEPENDENT DIAGNOSTIC LABORATORIES 122
10.6 CANCER RESEARCH INSTITUTES 123
10.7 OTHERS 124

11 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 125

11.1 OVERVIEW 126
11.2 DIRECT TENDER 129
11.3 RETAIL SALES 129

12 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION 131

12.1 OVERVIEW 132
12.2 NORTH AMERICA 137
- 12.2.1 U.S. 147
- 12.2.2 CANADA 152
- 12.2.3 MEXICO 157
12.3 EUROPE 162
- 12.3.1 GERMANY 172
- 12.3.2 U.K. 177
- 12.3.3 FRANCE 182
- 12.3.4 ITALY 187
- 12.3.5 RUSSIA 192
- 12.3.6 NETHERLANDS 197
- 12.3.7 SPAIN 202
- 12.3.8 SWEDEN 207
- 12.3.9 POLAND 212
- 12.3.10 BELGIUM 217
- 12.3.11 SWITZERLAND 222
- 12.3.12 DENMARK 227
- 12.3.13 NORWAY 232
- 12.3.14 FINLAND 237
- 12.3.15 TURKEY 242
- 12.3.16 REST OF EUROPE 247
12.4 ASIA-PACIFIC 248
- 12.4.1 AUSTRALIA 258
- 12.4.2 CHINA 263
- 12.4.3 INDIA 268
- 12.4.4 NEW ZEALAND 273
- 12.4.5 INDONESIA 278
- 12.4.6 JAPAN 283
- 12.4.7 THAILAND 288
- 12.4.8 PHILIPPINES 293
- 12.4.9 VIETNAM 298
- 12.4.10 MALAYSIA 303
- 12.4.11 SOUTH KOREA 308
- 12.4.12 SINGAPORE 313
- 12.4.13 TAIWAN 318
- 12.4.14 REST OF ASIA PACIFIC 323
12.5 SOUTH AMERICA 324
- 12.5.1 BRAZIL 334
- 12.5.2 ARGENTINA 339
- 12.5.3 REST OF SOUTH AMERICA 344
12.6 MIDDLE EAST AND AFRICA 345
- 12.6.1 SOUTH AFRICA 355
- 12.6.2 EGYPT 360
- 12.6.3 SAUDI ARABIA 365
- 12.6.4 U.A.E. 370
- 12.6.5 OMAN 375
- 12.6.6 KUWAIT 380
- 12.6.7 QATAR 385
- 12.6.8 BAHARAIN 390
- 12.6.9 REST OF MIDDLE EAST AND AFRICA 395

13 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 396

13.1 COMPANY SHARE ANALYSIS: GLOBAL 396
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 397
13.3 COMPANY SHARE ANALYSIS: EUROPE 398
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 399

14 SWOT ANALYSIS 400

15 COMPANY PROFILE 401

15.1 ABBOTT 401
- 15.1.1 COMPANY SNAPSHOT 401
- 15.1.2 REVENUE ANALYSIS 401
- 15.1.3 COMPANY SHARE ANALYSIS 402
- 15.1.4 PRODUCT PORTFOLIO 402
- 15.1.5 RECENT DEVELOPMENTS 402
15.2 ILLUMINA, INC. 403
- 15.2.1 COMPANY SNAPSHOT 403
- 15.2.2 REVENUE ANALYSIS 403
- 15.2.3 COMPANY SHARE ANALYSIS 404
- 15.2.4 PRODUCT PORTFOLIO 404
- 15.2.5 RECENT DEVELOPMENT 404
15.3 BIOMERIEUX SA 405
- 15.3.1 COMPANY SNAPSHOT 405
- 15.3.2 REVENUE ANALYSIS 405
- 15.3.3 COMPANY SHARE ANALYSIS 406
- 15.3.4 PRODUCT PORTFOLIO 406
- 15.3.5 RECENT DEVELOPMENTS 406
15.4 THERMO FISHER SCIENTIFIC INC. 407
- 15.4.1 COMPANY SNAPSHOT 407
- 15.4.2 REVENUE ANALYSIS 407
- 15.4.3 COMPANY SHARE ANALYSIS 408
- 15.4.4 PRODUCT PORTFOLIO 408
- 15.4.5 RECENT DEVELOPMENT 408
15.5 F. HOFFMANN-LA ROCHE LTD. 409
- 15.5.1 COMPANY SNAPSHOT 409
- 15.5.2 REVENUE ANALYSIS 409
- 15.5.3 COMPANY SHARE ANALYSIS 410
- 15.5.4 PRODUCT PORTFOLIO 410
- 15.5.5 RECENT DEVELOPMENT 410
15.6 AGILENT TECHNOLOGIES, INC. 411
- 15.6.1 COMPANY PROFILE 411
- 15.6.2 REVENUE ANALYSIS 411
- 15.6.3 PRODUCT PORTFOLIO 412
- 15.6.4 RECENT DEVELOPMENT 412
15.7 AMLO BIOSCIENCES LIMITED 413
- 15.7.1 COMPANY PROFILE 413
- 15.7.2 PRODUCT PORTFOLIO 413
- 15.7.3 RECENT DEVELOPMENT 413
15.8 CASTLE BIOSCIENCES INC 414
- 15.8.1 COMPANY SNAPSHOT 414
- 15.8.2 REVENUE ANALYSIS 414
- 15.8.3 PRODUCT PORTFOLIO 415
- 15.8.4 RECENT DEVELOPMENT 415
15.9 DAMAE MEDICAL 416
- 15.9.1 COMPANY PROFILE 416
- 15.9.2 PRODUCT PORTFOLIO 416
- 15.9.3 RECENT DEVELOPMENT 416
15.10 DERMLITE. 417
- 15.10.1 COMPANY PROFILE 417
- 15.10.2 PRODUCT PORTFOLIO 417
- 15.10.3 RECENT DEVELOPMENTS 417
15.11 DERMASENSOR 418
- 15.11.1 COMPANY PROFILE 418
- 15.11.2 PRODUCT PORTFOLIO 418
- 15.11.3 RECENT DEVELOPMENT 418

15.12 DERMTECH 419
- 15.12.1 COMPANY SNAPSHOT 419
- 15.12.2 REVENUE ANALYSIS 419
- 15.12.3 PRODUCT PORTFOLIO 420
- 15.12.4 RECENT DEVELOPMENT 420
15.13 INIVATA LTD. 421
- 15.13.1 COMPANY PROFILE 421
- 15.13.2 PRODUCT PORTFOLIO 421
- 15.13.3 RECENT DEVELOPMENT 421
15.14 MICHAEL DIAGNOSTICS LTD 422
- 15.14.1 COMPANY SNAPSHOT 422
- 15.14.2 PRODUCT PORTFOLIO 422
- 15.14.3 RECENT DEVELOPMENT 422
15.15 MYRIAD GENETICS, INC. 423
- 15.15.1 COMPANY SNAPSHOT 423
- 15.15.2 REVENUE ANALYSIS 423
- 15.15.3 PRODUCT PORTFOLIO 424
- 15.15.4 RECENT DEVELOPMENT 424
15.16 NANOSTRING 425
- 15.16.1 COMPANY SNAPSHOT 425
- 15.16.2 REVENUE ANALYSIS 425
- 15.16.3 PRODUCT PORTFOLIO 426
- 15.16.4 RECENT DEVELOPMENT 426
15.17 NERACARE GMBH 427
- 15.17.1 COMPANY PROFILE 427
- 15.17.2 PRODUCT PORTFOLIO 427
- 15.17.3 RECENT DEVELOPMENT 427
15.18 SKIN ANALYTICS 428
- 15.18.1 COMPANY PROFILE 428
- 15.18.2 PRODUCT PORTFOLIO 428
- 15.18.3 RECENT DEVELOPMENT 428
15.19 SKYLINEDX 429
- 15.19.1 COMPANY PROFILE 429
- 15.19.2 PRODUCT PORTFOLIO 429
- 15.19.3 RECENT DEVELOPMENTS 429
15.20 VERISKIN INC. 430
- 15.20.1 COMPANY PROFILE 430
- 15.20.2 PRODUCT PORTFOLIO 430
- 15.20.3 RECENT DEVELOPMENTS 430
15.21 QIAGEN 431
- 15.21.1 COMPANY SNAPSHOT 431
- 15.21.2 REVENUE ANALYSIS 431
- 15.21.3 PRODUCT PORTFOLIO 432
- 15.21.4 RECENT DEVELOPMENT 432
15.22 QUEST DIAGNOSTICS INCORPORATED (2022) 433
- 15.22.1 COMPANY SNAPSHOT 433
- 15.22.2 REVENUE ANALYSIS 433
- 15.22.3 PRODUCT PORTFOLIO 434
- 15.22.4 RECENT DEVELOPMENTS 434

16 QUESTIONNAIRE 435

17 RELATED REPORTS 438

LIST OF FIGURES

FIGURE 1 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: SEGMENTATION 54
FIGURE 2 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 57
FIGURE 3 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 58
FIGURE 4 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 59
FIGURE 5 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 59
FIGURE 6 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 62
FIGURE 7 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 63
FIGURE 8 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 64
FIGURE 9 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 65
FIGURE 10 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: SEGMENTATION 68
FIGURE 11 THE GROWING PREVALENCE OF MELANOMA CANCER AND THE INCREASING AWARENESS REGARDING MELANOMA CANCER ARE EXPECTED TO DRIVE THE GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030 69
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET IN 2023 & 2030 69
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 70
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR MELANOMA CANCER DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 71
FIGURE 15 ESTIMATED PREVALENCE OF MELANOMA CANCER IN 2020 75
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET 81
FIGURE 17 NUMBER OF NEW CASES IN 2018 IN FEMALES OF ALL AGES 83
FIGURE 18 AGEING EUROPE POPULATION (IN MILLION) 84
FIGURE 19 ESTIMATED LIFETIME CARE SPENDING 87
FIGURE 20 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 91
FIGURE 21 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 92
FIGURE 22 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 92
FIGURE 23 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 93
FIGURE 24 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 103
FIGURE 25 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 104
FIGURE 26 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 104
FIGURE 27 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 105
FIGURE 28 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, 2022 117
FIGURE 29 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 118
FIGURE 30 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 118
FIGURE 31 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 119
FIGURE 32 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 126
FIGURE 33 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 127
FIGURE 34 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 127
FIGURE 35 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 128
FIGURE 36 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 133
FIGURE 37 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY REGION (2022) 134
FIGURE 38 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY REGION (2023 & 2030) 134
FIGURE 39 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY REGION (2022 & 2030) 135
FIGURE 40 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023 & 2030) 135
FIGURE 41 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 138
FIGURE 42 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 139
FIGURE 43 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 139
FIGURE 44 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 140
FIGURE 45 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 140
FIGURE 46 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 163
FIGURE 47 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 164
FIGURE 48 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 164
FIGURE 49 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 165
FIGURE 50 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 165
FIGURE 51 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 249
FIGURE 52 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 250
FIGURE 53 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 250
FIGURE 54 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 251
FIGURE 55 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 251
FIGURE 56 SOUTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 325
FIGURE 57 SOUTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 326
FIGURE 58 SOUTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 326
FIGURE 59 SOUTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 327
FIGURE 60 SOUTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 327
FIGURE 61 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 346
FIGURE 62 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 347
FIGURE 63 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 347
FIGURE 64 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 348
FIGURE 65 MIDDLE EAST AND AFRICA MELANOMA CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 348
FIGURE 66 GLOBAL MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 396
FIGURE 67 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 397
FIGURE 68 EUROPE MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 398
FIGURE 69 ASIA-PACIFIC MELANOMA CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 399